Subject: Improving access to drugs
From: "EIU Healthcare" <[email-masked]>
To: David Sergeenko
Date: Tue, 12 Jun 2018 22:30:17 -0500 (CDT)

What is drug lag? The delay between when a drug is available in one country, to when it is available in other countries, with local regulatory approval used as the benchmark. Due to a significant body of work highlighting the costs and implications of this delay in access to innovative medicine, the global drug lag has decreased over time as local regulators rework their approval criteria to be more effective and efficient.

Here The Economist Intelligence Unit explains what is in the way of access to medicines:

Click here to view full infographic

We are running a series of infographics over the coming months in our monthly Healthcare newsletter. The EIU Healthcare newsletter provides you with the latest research, analysis and recommendations across the healthcare ecosystem. To sign up to the newsletter, please register using the button below.

SIGN UP

The Economist Group © 2018 All rights reserved.

The Economist Intelligence Unit

20 Cabot Square | London, E14 4QW | United Kingdom

To change your preferences for EIU communications or opt out from all communications',

please visit http://pages.eiu.com/SubsMgmt.html

This e-mail may contain confidential material.

If you are not an intended recipient, please notify the sender and delete all copies.

It may also contain personal views which are not the views of The Economist Group.

We may monitor e-mail to and from our network.

Sent by a member of The Economist Group.

The Group's parent company is The Economist Newspaper Limited,

registered in England with company number 236383 and

registered office at The Adelphi, 1-11 John Adam Street, London, WC2N 6HT

For Group company registration details go to http://legal.economistgroup.com